Expected 12-week outcome with AOD-9604: approximately 7-8.5 kg total weight loss, roughly 5.5-6.5 kg from fat, 1-2 kg from lean tissue and water
While supporters argue that regulated compounding could bring greater oversight to a largely grey-market sector, critics continue to question whether the available evidence supports wider clinical use
While Novo Nordisk and Eli Lilly might be at the forefront, the question will be for how long
It is available to patients with a body mass index (BMI) of over 30 kg/m or individuals with a BMI of over 27 kg/m alongside at least one weight-related condition, such as type 2 diabetes, prediabetes, high cholesterol, or sleep apnea
Key Scientific Features High-purity AOD9604 ( 98% by HPLC/MS, cyclized acetate salt form) Verified 16-amino-acid sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (disulfide bridge between Cys7Cys14) Lyophilized formulation for enhanced long-term stability Full Certificate of Analysis (COA) with HPLC, MS, and amino acid analysis Manufactured in GMP-aligned, ISO-compliant facilities Suitable for lipolytic assays, beta-3 AR modulation studies, and osteoarthritis research Research-Referenced Attributes (Based on scientific literature
